

Marc G Ghany

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8539396/publications.pdf>

Version: 2024-02-01

193
papers

20,695
citations

14655

66
h-index

9861

141
g-index

199
all docs

199
docs citations

199
times ranked

16321
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|---|------|-----------|
| 1 | A Prospective Cohort Study of Novel Markers of Hepatitis B Virus Replication in Human Immunodeficiency Virus Coinfection. <i>Clinical Gastroenterology and Hepatology</i> , 2023, 21, 125-135.e8. | 4.4 | 3 |
| 2 | A prospective cohort study of renal function and bone turnover in adults with hepatitis B virus (HBV)–HIV co-infection with high prevalence of tenofovir–based antiretroviral therapy use. <i>HIV Medicine</i> , 2023, 24, 55-74. | 2.2 | 2 |
| 3 | HBV transcription and translation persist despite viral suppression in HBV–HIV co-infected patients on antiretroviral therapy. <i>Hepatology</i> , 2023, 77, 594-605. | 7.3 | 2 |
| 4 | Performance of Serum-Based Scores for Identification of Mild Hepatic Steatosis in HBV Mono-infected and HBV–HIV Co-infected Adults. <i>Digestive Diseases and Sciences</i> , 2022, 67, 676-688. | 2.3 | 4 |
| 5 | Reply. <i>Hepatology</i> , 2022, 75, 761-763. | 7.3 | 0 |
| 6 | Systematic review with meta-analysis: the impact of functional cure on clinical outcomes in patients with chronic hepatitis B. <i>Alimentary Pharmacology and Therapeutics</i> , 2022, 55, 8-25. | 3.7 | 12 |
| 7 | Letter: systematic review with meta-analysis on the impact of functional cure on clinical outcomes in patients with chronic hepatitis B—authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2022, 55, 618-619. | 3.7 | 0 |
| 8 | Review article: hepatitis B—current and emerging therapies. <i>Alimentary Pharmacology and Therapeutics</i> , 2022, 55, 805-819. | 3.7 | 13 |
| 9 | Changes in serum hepatitis B surface and e antigen, interferon-inducible protein 10, and aminotransferase levels during combination therapy of immune-tolerant chronic hepatitis B. <i>Hepatology</i> , 2022, 76, 775-787. | 7.3 | 7 |
| 10 | Fatty Liver Disease in a Prospective North American Cohort of Adults With Human Immunodeficiency Virus and Hepatitis B Virus Coinfection. <i>Clinical Infectious Diseases</i> , 2021, 73, e3275-e3285. | 5.8 | 15 |
| 11 | Enhanced Screening for Hepatitis D in the USA: Overcoming the Δ Blues. <i>Digestive Diseases and Sciences</i> , 2021, 66, 2483-2485. | 2.3 | 7 |
| 12 | Liver Disease and Coronavirus Disease 2019: From Pathogenesis to Clinical Care. <i>Hepatology</i> , 2021, 74, 1088-1100. | 7.3 | 58 |
| 13 | Low Incidence of Adverse Outcomes in Adults With Chronic Hepatitis B Virus Infection in the Era of Antiviral Therapy. <i>Hepatology</i> , 2021, 73, 2124-2140. | 7.3 | 23 |
| 14 | Precore and Basal Core Promoter Hepatitis B Virus (HBV) Variants Are Present From a Young Age and Differ Across HBV Genotypes. <i>Hepatology</i> , 2021, 73, 1637-1651. | 7.3 | 11 |
| 15 | OUP accepted manuscript. <i>Clinical Infectious Diseases</i> , 2021, , . | 5.8 | 0 |
| 16 | Randomized Trial of a Vaccine Regimen to Prevent Chronic HCV Infection. <i>New England Journal of Medicine</i> , 2021, 384, 541-549. | 27.0 | 101 |
| 17 | The 2020 Nobel Prize for Medicine or Physiology for the Discovery of Hepatitis C Virus: A Triumph of Curiosity and Persistence. <i>Hepatology</i> , 2021, 74, 2813-2823. | 7.3 | 4 |
| 18 | Clearance of pegylated interferon by Kupffer cells limits NK cell activation and therapy response of patients with HBV infection. <i>Science Translational Medicine</i> , 2021, 13, . | 12.4 | 18 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 19 | Hepatic Steatosis and Steatohepatitis in a Large North American Cohort of Adults With Chronic Hepatitis B. American Journal of Gastroenterology, 2021, 116, 1686-1697. | 0.4 | 20 |
| 20 | Liver disease symptoms are associated with higher risk of adverse clinical outcomes: A longitudinal study of North American adults with chronic Hepatitis B. GastroHep, 2021, 3, 196-208. | 0.6 | 1 |
| 21 | Clinical significance of quantitative e antigen in a cohort of hepatitis B virus-infected children and adults in North America. Journal of Viral Hepatitis, 2021, 28, 1042-1056. | 2.0 | 5 |
| 22 | A Prospective Study Evaluating Changes in Histology, Clinical and Virologic Outcomes in HBV/HIV Co-infected Adults in North America. Hepatology, 2021, 74, 1174-1189. | 7.3 | 11 |
| 23 | Prospective Study of Withdrawal of Antiviral Therapy in Patients with Chronic Hepatitis B after Prolonged Virological Response. Hepatology Communications, 2021, 5, 1888-1900. | 4.3 | 3 |
| 24 | Hepatitis B e antigen loss in adults and children with chronic hepatitis B living in North America: A prospective cohort study. Journal of Viral Hepatitis, 2021, 28, 1526-1538. | 2.0 | 6 |
| 25 | Comparison of HBV RNA and Hepatitis B Core Related Antigen With Conventional HBV Markers Among Untreated Adults With Chronic Hepatitis B in North America. Hepatology, 2021, 74, 2395-2409. | 7.3 | 36 |
| 26 | Spontaneous Clearance of Drug-Resistant Chronic Hepatitis C Virus Infection. Hepatology, 2021, 74, 3552-3553. | 7.3 | 1 |
| 27 | Evaluating Noninvasive Markers to Identify Advanced Fibrosis by Liver Biopsy in HBV/HIV Co-infected Adults. Hepatology, 2020, 71, 411-421. | 7.3 | 23 |
| 28 | Durability of Spontaneous and Treatment-Related Loss of Hepatitis B s Antigen. Clinical Gastroenterology and Hepatology, 2020, 18, 700-709.e3. | 4.4 | 44 |
| 29 | Hepatitis B and C virus infection and risk of haematological malignancies. Journal of Viral Hepatitis, 2020, 27, 4-12. | 2.0 | 9 |
| 30 | Guidance for Design and Endpoints of Clinical Trials in Chronic Hepatitis B Report From the 2019 EASL-AASLD HBV Treatment Endpoints Conference. Hepatology, 2020, 71, 1070-1092. | 7.3 | 52 |
| 31 | Durability of Hepatitis B Surface Antigen Loss With Nucleotide Analogue and Peginterferon Therapy in Patients With Chronic Hepatitis B. Hepatology Communications, 2020, 4, 8-20. | 4.3 | 43 |
| 32 | Guidance for design and endpoints of clinical trials in chronic hepatitis B - Report from the 2019 EASL-AASLD HBV Treatment Endpoints Conference. Journal of Hepatology, 2020, 72, 539-557. | 3.7 | 208 |
| 33 | Hepatitis C Guidance 2019 Update: American Association for the Study of Liver Diseases Infectious Diseases Society of America Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection. Hepatology, 2020, 71, 686-721. | 7.3 | 526 |
| 34 | Hepatic Histology in Treatment-naïve Children With Chronic Hepatitis B Infection Living in the United States and Canada. Journal of Pediatric Gastroenterology and Nutrition, 2020, 71, 99-105. | 1.8 | 6 |
| 35 | Alcohol, tobacco and coffee consumption and liver disease severity among individuals with Chronic Hepatitis B infection in North America. Annals of Hepatology, 2020, 19, 437-445. | 1.5 | 6 |
| 36 | Serum alanine aminotransferase flares in chronic hepatitis B infection: the good and the bad. The Lancet Gastroenterology and Hepatology, 2020, 5, 406-417. | 8.1 | 64 |

| # | ARTICLE | IF | CITATIONS |
|----|--|------|-----------|
| 37 | Hepatitis B. Gastroenterology Clinics of North America, 2020, 49, 215-238. | 2.2 | 36 |
| 38 | Entecavir and Peginterferon Alfa-2a in Adults With Hepatitis B e Antigen-Positive Immune-Tolerant Chronic Hepatitis B Virus Infection. Hepatology, 2019, 69, 2338-2348. | 7.3 | 37 |
| 39 | WHO Guidelines for Prevention, Care and Treatment of Individuals Infected with HBV. Clinics in Liver Disease, 2019, 23, 417-432. | 2.1 | 36 |
| 40 | Longitudinal effects of Nucleos(t)ide analogue therapy in chronic hepatitis B patients and the utility of non-invasive fibrosis markers during treatment: A single-center experience for up to 17 years. Antiviral Research, 2019, 168, 61-67. | 4.1 | 3 |
| 41 | Age, race and viral genotype are associated with the prevalence of hepatitis B e antigen in children and adults with chronic hepatitis B. Journal of Viral Hepatitis, 2019, 26, 856-865. | 2.0 | 17 |
| 42 | Association Between Severe Serum Alanine Aminotransferase Flares and Hepatitis B e Antigen Seroconversion and HBV DNA Decrease in Untreated Patients With Chronic HBV Infection. Clinical Gastroenterology and Hepatology, 2019, 17, 2541-2551.e2. | 4.4 | 28 |
| 43 | Phase Transition Is Infrequent Among North American Adults With e-Antigen-Negative Chronic Hepatitis B and Low-Level Viremia. American Journal of Gastroenterology, 2019, 114, 1753-1763. | 0.4 | 17 |
| 44 | Spectrum of Liver Disease in Hepatitis B Virus (HBV) Patients Co-infected with Human Immunodeficiency Virus (HIV): Results of the HBV-HIV Cohort Study. American Journal of Gastroenterology, 2019, 114, 746-757. | 0.4 | 33 |
| 45 | Defective glycosylation and multisystem abnormalities characterize the primary immunodeficiency XMEN disease. Journal of Clinical Investigation, 2019, 130, 507-522. | 8.2 | 74 |
| 46 | Baseline Intrahepatic and Peripheral Innate Immunity are Associated with Hepatitis C Virus Clearance During Direct-Acting Antiviral Therapy. Hepatology, 2018, 68, 2078-2088. | 7.3 | 38 |
| 47 | Hepatitis C Guidance 2018 Update: AASLD-IDSA Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection. Clinical Infectious Diseases, 2018, 67, 1477-1492. | 5.8 | 509 |
| 48 | EASL International Recognition Award Recipient 2018: Prof. Anna Lok. Journal of Hepatology, 2018, 68, 881-882. | 3.7 | 0 |
| 49 | Disease Pathways and Mechanisms of Potential Drug Targets. Clinical Liver Disease, 2018, 12, 12-18. | 2.1 | 4 |
| 50 | Rapid decrease in hepatitis C viremia by direct acting antivirals improves the natural killer cell response to IFN- γ . Gut, 2017, 66, 724-735. | 12.1 | 55 |
| 51 | Prospective phenotyping of NGLY1-CDDG, the first congenital disorder of deglycosylation. Genetics in Medicine, 2017, 19, 160-168. | 2.4 | 124 |
| 52 | Complications of percutaneous liver biopsy with Klatskin needles: a 36-year single-centre experience. Alimentary Pharmacology and Therapeutics, 2017, 45, 744-753. | 3.7 | 54 |
| 53 | Current treatment guidelines of chronic hepatitis B: The role of nucleos(t)ide analogues and peginterferon. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2017, 31, 299-309. | 2.4 | 54 |
| 54 | Prevalence of hepatitis B antiviral drug resistance variants in North American patients with chronic hepatitis B not receiving antiviral treatment. Journal of Viral Hepatitis, 2017, 24, 1032-1042. | 2.0 | 10 |

| # | ARTICLE | IF | CITATIONS |
|----|--|------|-----------|
| 55 | Characteristics of US-Born Versus Foreign-Born Americans of African Descent With Chronic Hepatitis B. <i>American Journal of Epidemiology</i> , 2017, 186, 356-366. | 3.4 | 15 |
| 56 | Determination of hepatitis B phenotype using biochemical and serological markers. <i>Journal of Viral Hepatitis</i> , 2017, 24, 320-329. | 2.0 | 55 |
| 57 | NAM 2017 report: A national plan to eliminate hepatitis B and C in the United States by 2030 and the AASLD's response. <i>Hepatology</i> , 2017, 66, 1020-1022. | 7.3 | 9 |
| 58 | Hepatitis B cure: From discovery to regulatory approval. <i>Journal of Hepatology</i> , 2017, 67, 847-861. | 3.7 | 189 |
| 59 | Hepatitis B cure: From discovery to regulatory approval. <i>Hepatology</i> , 2017, 66, 1296-1313. | 7.3 | 235 |
| 60 | Intra-Hepatic Depletion of Mucosal-Associated Invariant T Cells in Hepatitis C Virus-Induced Liver Inflammation. <i>Gastroenterology</i> , 2017, 153, 1392-1403.e2. | 1.3 | 87 |
| 61 | Cellular microRNA networks regulate host dependency of hepatitis C virus infection. <i>Nature Communications</i> , 2017, 8, 1789. | 12.8 | 70 |
| 62 | Long-term lamivudine therapy in chronic hepatitis B. <i>Alimentary Pharmacology and Therapeutics</i> , 2016, 44, 380-389. | 3.7 | 14 |
| 63 | Hepatitis E Virus Does Not Contribute to Hepatic Decompensation Among Patients With Advanced Chronic Hepatitis C. <i>Clinical Gastroenterology and Hepatology</i> , 2016, 14, 896-902. | 4.4 | 8 |
| 64 | Hepatitis B Virus-Specific and Global T-Cell Dysfunction in Chronic Hepatitis B. <i>Gastroenterology</i> , 2016, 150, 684-695.e5. | 1.3 | 178 |
| 65 | Natural History of Chronic Hepatitis C. , 2016, , 3-55. | | 2 |
| 66 | Should Family Physicians Routinely Screen Patients for Hepatitis C? Yes: Screening Makes Sense for High-Risk Adults. <i>American Family Physician</i> , 2016, 93, 15-6. | 0.1 | 0 |
| 67 | Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus. <i>Hepatology</i> , 2015, 62, 932-954. | 7.3 | 1,139 |
| 68 | Screening for hepatitis B virus to prevent viral reactivation – who and when?. <i>Clinical Liver Disease</i> , 2015, 5, 47-50. | 2.1 | 6 |
| 69 | Present and future therapies of hepatitis B: From discovery to cure. <i>Hepatology</i> , 2015, 62, 1893-1908. | 7.3 | 269 |
| 70 | Diabetes and prediabetes in patients with hepatitis B residing in North America. <i>Hepatology</i> , 2015, 62, 1364-1374. | 7.3 | 29 |
| 71 | A Cure for the High Cost of Hepatitis C Virus Treatment. <i>Annals of Internal Medicine</i> , 2015, 162, 660-661. | 3.9 | 12 |
| 72 | Successful Interferon-Free Therapy of Chronic Hepatitis C Virus Infection Normalizes Natural Killer Cell Function. <i>Gastroenterology</i> , 2015, 149, 190-200.e2. | 1.3 | 222 |

| # | ARTICLE | IF | CITATIONS |
|----|--|------|-----------|
| 73 | The Ongoing Debate of Who to Treat for Chronic Hepatitis C Virus. JAMA Internal Medicine, 2015, 175, 169. | 5.1 | 10 |
| 74 | An Epidemiologic Investigation of a Case of Acute Hepatitis E. Journal of Clinical Microbiology, 2015, 53, 3547-3552. | 3.9 | 11 |
| 75 | Natural History of Hepatitis C. Gastroenterology Clinics of North America, 2015, 44, 717-734. | 2.2 | 177 |
| 76 | Characteristics of Adults in the Hepatitis B Research Network in North America Reflect Their Country of Origin and Hepatitis B Virus Genotype. Clinical Gastroenterology and Hepatology, 2015, 13, 183-192. | 4.4 | 90 |
| 77 | Durability of Antibody Response Against Hepatitis B Virus in Healthcare Workers Vaccinated as Adults. Clinical Infectious Diseases, 2015, 60, 505-513. | 5.8 | 55 |
| 78 | Building Bridges and Providing Transparency to the Hepatitis C Virus Drug Approval Process. Gastroenterology, 2014, 147, 1201-1203. | 1.3 | 0 |
| 79 | Long-term therapy of chronic delta hepatitis with peginterferon alfa. Alimentary Pharmacology and Therapeutics, 2014, 40, 93-104. | 3.7 | 90 |
| 80 | Reply. Hepatology, 2014, 59, 1651-1651. | 7.3 | 1 |
| 81 | Effect of ribavirin on viral kinetics and liver gene expression in chronic hepatitis C. Gut, 2014, 63, 161-169. | 12.1 | 51 |
| 82 | Therapy of Hepatitis C “Back to the Future. New England Journal of Medicine, 2014, 370, 2043-2047. | 27.0 | 102 |
| 83 | QUEST for a cure for hepatitis C virus: the end is in sight. Lancet, The, 2014, 384, 381-383. | 13.7 | 7 |
| 84 | HARVEY ALTER AND MICHAEL HOUGHTON: THE DISCOVERY OF HEPATITIS C AND THE INTRODUCTION OF SCREENING TO PREVENT ITS TRANSMISSION IN TRANSFUSED BLOOD. , 2014, , 197-214. | | 1 |
| 85 | Spontaneous Mutations in the HBV Genome and their Clinical Implications. Current Hepatitis Reports, 2013, 12, 79-87. | 0.3 | 3 |
| 86 | The Hepatitis B Vaccine Protects Re-Exposed Health Care Workers, But Does Not Provide Sterilizing Immunity. Gastroenterology, 2013, 145, 1026-1034. | 1.3 | 47 |
| 87 | Hepatitis B virus treatment: Management of antiviral drug resistance. Clinical Liver Disease, 2013, 2, 24-28. | 2.1 | 7 |
| 88 | Hepatitis E: The nonendemic perspective. Clinical Liver Disease, 2013, 2, 245-249. | 2.1 | 1 |
| 89 | Discordance Among Transient Elastography, Aspartate Aminotransferase to Platelet Ratio Index, and Histologic Assessments of Liver Fibrosis in Patients With Chronic Hepatitis C. Clinical Gastroenterology and Hepatology, 2013, 11, 303-308.e1. | 4.4 | 29 |
| 90 | The liver diseases of lipodystrophy: The long-term effect of leptin treatment. Journal of Hepatology, 2013, 59, 131-137. | 3.7 | 138 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|------|-----------|
| 91 | Long-term outcome of chronic hepatitis C after sustained virological response to interferon-based therapy. <i>Alimentary Pharmacology and Therapeutics</i> , 2013, 37, 887-894. | 3.7 | 44 |
| 92 | Association of IL28B genotype with fibrosis progression and clinical outcomes in patients with chronic hepatitis C: A longitudinal analysis. <i>Hepatology</i> , 2013, 58, 1548-1557. | 7.3 | 96 |
| 93 | Acute hepatitis C: to treat or not to treat. <i>Lancet Infectious Diseases</i> , The, 2013, 13, 467-468. | 9.1 | 3 |
| 94 | Current and Future Therapies for Hepatitis C Virus Infection. <i>New England Journal of Medicine</i> , 2013, 368, 1907-1917. | 27.0 | 418 |
| 95 | What the Infectious Disease Physician Needs to Know About Pegylated Interferon and Ribavirin. <i>Clinical Infectious Diseases</i> , 2013, 56, 1629-1636. | 5.8 | 23 |
| 96 | Current and Future Therapies for Hepatitis C Virus Infection. <i>New England Journal of Medicine</i> , 2013, 369, 679-680. | 27.0 | 45 |
| 97 | Reduction in Hepatic Inflammation Is Associated With Less Fibrosis Progression and Fewer Clinical Outcomes in Advanced Hepatitis C. <i>American Journal of Gastroenterology</i> , 2012, 107, 1388-1398. | 0.4 | 14 |
| 98 | A 25-Year Study of the Clinical and Histologic Outcomes of Hepatitis C Virus Infection and Its Modes of Transmission in a Cohort of Initially Asymptomatic Blood Donors. <i>Journal of Infectious Diseases</i> , 2012, 206, 654-661. | 4.0 | 28 |
| 99 | The Application and Mechanism of Action of Ribavirin in Therapy of Hepatitis C. <i>Antiviral Chemistry and Chemotherapy</i> , 2012, 23, 1-12. | 0.6 | 109 |
| 100 | Tenofovir Disoproxil Fumarate for Prevention of Vertical Transmission of Hepatitis B Virus Infection by Highly Viremic Pregnant Women: A Case Series. <i>Digestive Diseases and Sciences</i> , 2012, 57, 2423-2429. | 2.3 | 106 |
| 101 | Randomised clinical trial: the benefit of combination therapy with adefovir and lamivudine for chronic hepatitis B. <i>Alimentary Pharmacology and Therapeutics</i> , 2012, 35, 1027-1035. | 3.7 | 19 |
| 102 | The new standard of HCV therapy: Retreatment in experienced patients. <i>Clinical Liver Disease</i> , 2012, 1, 16-19. | 2.1 | 0 |
| 103 | Renal tubular dysfunction during long-term adefovir or tenofovir therapy in chronic hepatitis B. <i>Alimentary Pharmacology and Therapeutics</i> , 2012, 35, 1317-1325. | 3.7 | 135 |
| 104 | S-Adenosyl Methionine Improves Early Viral Responses and Interferon-Stimulated Gene Induction in Hepatitis C Nonresponders. <i>Gastroenterology</i> , 2011, 140, 830-839.e3. | 1.3 | 51 |
| 105 | Maintenance Peginterferon Therapy and Other Factors Associated With Hepatocellular Carcinoma in Patients With Advanced Hepatitis C. <i>Gastroenterology</i> , 2011, 140, 840-849.e1. | 1.3 | 178 |
| 106 | Excess mortality in patients with advanced chronic hepatitis C treated with long-term peginterferon. <i>Hepatology</i> , 2011, 53, 1100-1108. | 7.3 | 55 |
| 107 | A prospective study of the rate of progression in compensated, histologically advanced chronic hepatitis C. <i>Hepatology</i> , 2011, 54, 396-405. | 7.3 | 142 |
| 108 | Predicting clinical outcomes using baseline and follow-up laboratory data from the hepatitis C long-term treatment against cirrhosis trial. <i>Hepatology</i> , 2011, 54, 1527-1537. | 7.3 | 27 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 109 | An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases. <i>Hepatology</i> , 2011, 54, 1433-1444. | 7.3 | 961 |
| 110 | Development and Progression of Portal Hypertensive Gastropathy in Patients With Chronic Hepatitis C. <i>American Journal of Gastroenterology</i> , 2011, 106, 884-893. | 0.4 | 16 |
| 111 | Prognostic value of Ishak fibrosis stage: Findings from the hepatitis C antiviral long-term treatment against cirrhosis trial. <i>Hepatology</i> , 2010, 51, 585-594. | 7.3 | 155 |
| 112 | Outcome of sustained virological responders with histologically advanced chronic hepatitis C. <i>Hepatology</i> , 2010, 52, 833-844. | 7.3 | 428 |
| 113 | Changes in quality of life and sexual health are associated with low-dose peginterferon therapy and disease progression in patients with chronic hepatitis C. <i>Alimentary Pharmacology and Therapeutics</i> , 2010, 31, 719-734. | 3.7 | 22 |
| 114 | Low- and standard-dose peginterferon alfa-2a for chronic hepatitis C, genotype 2 or 3: efficacy, tolerability, viral kinetics and cytokine response. <i>Alimentary Pharmacology and Therapeutics</i> , 2010, 31, 1018-1027. | 3.7 | 8 |
| 115 | Hepatitis C progressing to hepatocellular carcinoma: the HCV dialysis patient in dilemma. <i>Journal of Viral Hepatitis</i> , 2010, 17, 59-64. | 2.0 | 18 |
| 116 | Editorial : Treatment of Patients With HCV-Related Cirrhosis With Peginterferon and Ribavirin: Swinging the Pendulum Toward Treatment. <i>American Journal of Gastroenterology</i> , 2010, 105, 2174-2176. | 0.4 | 5 |
| 117 | Management of Untreated and Nonresponder Patients with Chronic Hepatitis C. <i>Seminars in Liver Disease</i> , 2010, 30, 348-360. | 3.6 | 7 |
| 118 | Hepatitis B Virology for Clinicians. <i>Clinics in Liver Disease</i> , 2010, 14, 397-408. | 2.1 | 17 |
| 119 | Pharmacokinetics and Pharmacodynamics of Peginterferon and Ribavirin: Implications for Clinical Efficacy in the Treatment of Chronic Hepatitis C. <i>Gastroenterology Clinics of North America</i> , 2010, 39, 649-658. | 2.2 | 24 |
| 120 | Natural Killer Cells Are Polarized Toward Cytotoxicity in Chronic Hepatitis C in an Interferon-Alpha-Dependent Manner. <i>Gastroenterology</i> , 2010, 138, 325-335.e2. | 1.3 | 243 |
| 121 | Predicting Clinical and Histologic Outcomes Based on Standard Laboratory Tests in Advanced Chronic Hepatitis C. <i>Gastroenterology</i> , 2010, 138, 136-146. | 1.3 | 82 |
| 122 | Factors That Determine the Development and Progression of Gastroesophageal Varices in Patients With Chronic Hepatitis C. <i>Gastroenterology</i> , 2010, 138, 2321-2331.e2. | 1.3 | 38 |
| 123 | Ribavirin Improves Early Responses to Peginterferon Through Improved Interferon Signaling. <i>Gastroenterology</i> , 2010, 139, 154-162.e4. | 1.3 | 108 |
| 124 | Complication Rate of Percutaneous Liver Biopsies Among Persons With Advanced Chronic Liver Disease in the HALT-C Trial. <i>Clinical Gastroenterology and Hepatology</i> , 2010, 8, 877-883. | 4.4 | 385 |
| 125 | Diagnosis, management, and treatment of hepatitis C: An update. <i>Hepatology</i> , 2009, 49, 1335-1374. | 7.3 | 2,610 |
| 126 | Evolution of hepatic steatosis in patients with advanced hepatitis C: Results from the hepatitis C antiviral long-term treatment against cirrhosis (HALT-C) trial. <i>Hepatology</i> , 2009, 49, 1828-1837. | 7.3 | 51 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|------|-----------|
| 127 | Variants in interferon-alpha pathway genes and response to pegylated interferon-Alpha2a plus ribavirin for treatment of chronic hepatitis C virus infection in the hepatitis C antiviral long-term treatment against cirrhosis trial. Hepatology, 2009, 49, 1847-1858. | 7.3 | 75 |
| 128 | Antiviral resistance and hepatitis B therapy. Hepatology, 2009, 49, S174-S184. | 7.3 | 189 |
| 129 | Human immunodeficiency virus and hepatitis C infections induce distinct immunologic imprints in peripheral mononuclear cells. Hepatology, 2009, 50, 34-45. | 7.3 | 44 |
| 130 | Reply:. Hepatology, 2009, 50, 324-325. | 7.3 | 3 |
| 131 | Coffee intake is associated with lower rates of liver disease progression in chronic hepatitis C. Hepatology, 2009, 50, 1360-1369. | 7.3 | 153 |
| 132 | Fibrosis progression in chronic hepatitis C: Morphometric image analysis in the HALT-C trial. Hepatology, 2009, 50, 1738-1749. | 7.3 | 60 |
| 133 | Incidence of Hepatocellular Carcinoma and Associated Risk Factors in Hepatitis C-Related Advanced Liver Disease. Gastroenterology, 2009, 136, 138-148. | 1.3 | 570 |
| 134 | Weight-Related Effects on Disease Progression in the Hepatitis C Antiviral Long-Term Treatment Against Cirrhosis Trial. Gastroenterology, 2009, 137, 549-557. | 1.3 | 125 |
| 135 | Effect of HCV RNA Suppression During Peginterferon Alfa-2a Maintenance Therapy on Clinical Outcomes in the HALT-C Trial. Gastroenterology, 2009, 137, 1986-1994. | 1.3 | 31 |
| 136 | Management of Antiviral Resistance in Chronic Hepatitis B. , 2009, , 273-287. | | 0 |
| 137 | Herbal product use by persons enrolled in the hepatitis C Antiviral Long-Term Treatment Against Cirrhosis (HALT-C) Trial. Hepatology, 2008, 47, 605-612. | 7.3 | 114 |
| 138 | Interpretation of positive transcription-mediated amplification test results from polymerase chain reaction-negative samples obtained after treatment of chronic hepatitis C. Hepatology, 2008, 48, 1412-1419. | 7.3 | 23 |
| 139 | DNA polymorphisms and response to treatment in patients with chronic hepatitis C: Results from the HALT-C trial. Journal of Hepatology, 2008, 49, 548-556. | 3.7 | 43 |
| 140 | Blunted Cytopenias and Weight Loss: New Correlates of Virologic Null Response to Re-treatment of Chronic Hepatitis C. Clinical Gastroenterology and Hepatology, 2008, 6, 234-241. | 4.4 | 26 |
| 141 | Prolonged Therapy of Advanced Chronic Hepatitis C with Low-Dose Peginterferon. New England Journal of Medicine, 2008, 359, 2429-2441. | 27.0 | 445 |
| 142 | Association between Body Mass Index and Diabetes and Hepatocellular Carcinoma. Annals of Internal Medicine, 2008, 148, 166. | 3.9 | 2 |
| 143 | Evolution of Therapy for Chronic Hepatitis B: Progressing from the Simple to the Complex. Annals of Internal Medicine, 2007, 147, 806. | 3.9 | 5 |
| 144 | Health-related quality of life in patients with chronic hepatitis C and advanced fibrosis. Journal of Hepatology, 2007, 46, 420-431. | 3.7 | 125 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 145 | Hepatic Steatosis in Hepatitis C: Comparison of Diabetic and Nondiabetic Patients in the Hepatitis C Antiviral Long-Term Treatment Against Cirrhosis Trial. <i>Clinical Gastroenterology and Hepatology</i> , 2007, 5, 245-254. | 4.4 | 46 |
| 146 | Impact of Reducing Peginterferon Alfa-2a and Ribavirin Dose During Retreatment in Patients With Chronic Hepatitis C. <i>Gastroenterology</i> , 2007, 132, 103-112. | 1.3 | 200 |
| 147 | Drug Targets and Molecular Mechanisms of Drug Resistance in Chronic Hepatitis B. <i>Gastroenterology</i> , 2007, 132, 1574-1585. | 1.3 | 154 |
| 148 | Mutation Rate of the Hepatitis C Virus NS5B in Patients Undergoing Treatment With Ribavirin Monotherapy. <i>Gastroenterology</i> , 2007, 132, 1757-1766. | 1.3 | 105 |
| 149 | Two Cases of Thyroid Storm-Associated Cholestatic Jaundice. <i>Endocrine Practice</i> , 2007, 13, 476-480. | 2.1 | 48 |
| 150 | Myxovirus-1 and protein kinase haplotypes and fibrosis in chronic hepatitis C virus. <i>Hepatology</i> , 2007, 46, 74-83. | 7.3 | 11 |
| 151 | The effects of discontinuing pioglitazone in patients with nonalcoholic steatohepatitis. <i>Hepatology</i> , 2007, 46, 424-429. | 7.3 | 227 |
| 152 | Antiviral drug-resistant HBV: Standardization of nomenclature and assays and recommendations for management. <i>Hepatology</i> , 2007, 46, 254-265. | 7.3 | 418 |
| 153 | Efforts to Define the Natural History of Chronic Hepatitis C Continue. <i>Clinical Gastroenterology and Hepatology</i> , 2006, 4, 1190-1192. | 4.4 | 5 |
| 154 | Assessment and Management of Chronic Hepatitis B. <i>Infectious Disease Clinics of North America</i> , 2006, 20, 63-79. | 5.1 | 8 |
| 155 | Changes in Serum Adipokine Levels During Pioglitazone Treatment for Nonalcoholic Steatohepatitis: Relationship to Histological Improvement. <i>Clinical Gastroenterology and Hepatology</i> , 2006, 4, 1048-1052. | 4.4 | 90 |
| 156 | Roles of Iron and HFE Mutations on Severity and Response to Therapy During Retreatment of Advanced Chronic Hepatitis C. <i>Gastroenterology</i> , 2006, 131, 1440-1451. | 1.3 | 83 |
| 157 | The prevalence and risk factors associated with esophageal varices in subjects with hepatitis C and advanced fibrosis. <i>Gastrointestinal Endoscopy</i> , 2006, 64, 855-864. | 1.0 | 94 |
| 158 | Natural history of hbeag-negative chronic Hepatitis b. <i>Current Hepatitis Reports</i> , 2006, 5, 27-32. | 0.3 | 0 |
| 159 | Steatosis and progression of fibrosis in untreated patients with chronic hepatitis C infection. <i>Hepatology</i> , 2006, 43, 780-787. | 7.3 | 70 |
| 160 | HCV RNA detection by TMA during the hepatitis C antiviral long-term treatment against cirrhosis (Halt-C) trial. <i>Hepatology</i> , 2006, 44, 360-367. | 7.3 | 46 |
| 161 | Modeling hepatic fibrosis in African American and Caucasian American patients with chronic hepatitis C virus infection. <i>Hepatology</i> , 2006, 44, 925-935. | 7.3 | 53 |
| 162 | Impact of disease severity on outcome of antiviral therapy for chronic hepatitis C: Lessons from the HALT-C trial. <i>Hepatology</i> , 2006, 44, 1675-1684. | 7.3 | 145 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 163 | Portal Hypertensive Gastropathy in Chronic Hepatitis C Patients with Bridging Fibrosis and Compensated Cirrhosis: Results from the HALT-C Trial. American Journal of Gastroenterology, 2006, 101, 983-992. | 0.4 | 61 |
| 164 | Pushing the treatment envelope for chronic hepatitis C? is more necessarily better?. Hepatology, 2005, 41, 234-236. | 7.3 | 6 |
| 165 | Leptin reverses nonalcoholic steatohepatitis in patients with severe lipodystrophy. Hepatology, 2005, 41, 753-760. | 7.3 | 210 |
| 166 | Predicting cirrhosis in patients with hepatitis C based on standard laboratory tests: Results of the HALT-C cohort. Hepatology, 2005, 42, 282-292. | 7.3 | 299 |
| 167 | Assessment of liver fibrosis: Palpate, poke or pulse?. Hepatology, 2005, 42, 759-761. | 7.3 | 19 |
| 168 | Pilot study of interferon gamma for chronic hepatitis C. Journal of Hepatology, 2005, 43, 67-71. | 3.7 | 32 |
| 169 | Serum alpha-fetoprotein levels in patients with advanced hepatitis C: Results from the HALT-C Trial. Journal of Hepatology, 2005, 43, 434-441. | 3.7 | 310 |
| 170 | Expression of Chemokine and Inhibitory Receptors on Natural Killer Cells: Effect of Immune Activation and HIV Viremia. Journal of Infectious Diseases, 2004, 189, 1193-1198. | 4.0 | 75 |
| 171 | Cellular Immune Responses to the Hepatitis B Virus Polymerase. Journal of Immunology, 2004, 173, 5863-5871. | 0.8 | 86 |
| 172 | Evolution of the HALT-C Trial: pegylated interferon as maintenance therapy for chronic hepatitis C in previous interferon nonresponders. Contemporary Clinical Trials, 2004, 25, 472-492. | 1.9 | 160 |
| 173 | A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis. Hepatology, 2004, 39, 188-196. | 7.3 | 679 |
| 174 | Management of chronic hepatitis B. Gastroenterology Clinics of North America, 2004, 33, 563-579. | 2.2 | 2 |
| 175 | Peginterferon Alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior treatment[1], [2] and [3] 1 2 3â††. Gastroenterology, 2004, 126, 1015-1023. | 1.3 | 436 |
| 176 | Maintenance therapy with ribavirin in patients with chronic hepatitis C who fail to respond to combination therapy with interferon alfa and ribavirin. Hepatology, 2003, 38, 66-74. | 7.3 | 83 |
| 177 | E1 therapeutic vaccination for chronic hepatitis C: All that glitters is not gold. Hepatology, 2003, 38, 1092-1094. | 7.3 | 1 |
| 178 | A rapid immunochromatographic assay for hepatitis B virus screening. Journal of Viral Hepatitis, 2003, 10, 331-334. | 2.0 | 28 |
| 179 | Progression of fibrosis in chronic hepatitis C. Gastroenterology, 2003, 124, 97-104. | 1.3 | 368 |
| 180 | Associations of chemokine system polymorphisms with clinical outcomes and treatment responses of chronic hepatitis C. Gastroenterology, 2003, 124, 352-360. | 1.3 | 124 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|------|-----------|
| 181 | Hepatitis B e Antigen " The Dangerous Endgame of Hepatitis B. New England Journal of Medicine, 2002, 347, 208-210. | 27.0 | 31 |
| 182 | Neutropenia during combination therapy of interferon alfa and ribavirin for chronic hepatitis C. Hepatology, 2002, 36, 1273-1279. | 7.3 | 182 |
| 183 | Transcription-mediated amplification is more sensitive than conventional PCR-based assays for detecting residual serum HCV RNA at end of treatment. American Journal of Gastroenterology, 2001, 96, 2968-2972. | 0.4 | 66 |
| 184 | Stability of HCV-RNA level and its lack of correlation with disease severity in asymptomatic chronic hepatitis C virus carriers. Journal of Viral Hepatitis, 2001, 8, 256-263. | 2.0 | 42 |
| 185 | 16 Hepatitis C virus and human immunodeficiency virus coinfection. Biomedical Research Reports, 2000, 2, 315-328. | 0.3 | 0 |
| 186 | Long-Term Therapy of Chronic Hepatitis B With Lamivudine. Hepatology, 2000, 32, 828-834. | 7.3 | 326 |
| 187 | Hepatitis B virus S mutants in liver transplant recipients who were reinfected despite hepatitis B immune globulin prophylaxis. Hepatology, 1998, 27, 213-222. | 7.3 | 324 |
| 188 | 10-year follow-up after interferon-? therapy for chronic hepatitis C. Hepatology, 1998, 28, 1121-1127. | 7.3 | 275 |
| 189 | Predictive value of aminotransferase and hepatitis B virus DNA levels on response to interferon therapy for chronic hepatitis B. Journal of Viral Hepatitis, 1998, 5, 171-178. | 2.0 | 39 |
| 190 | Correlation between serum HCV RNA and aminotransferase levels in patients with chronic HCV infection. Digestive Diseases and Sciences, 1996, 41, 2213-2218. | 2.3 | 24 |
| 191 | Effect of human immunodeficiency virus infection on hepatitis C virus infection in hemophiliacs. Digestive Diseases and Sciences, 1996, 41, 1265-1272. | 2.3 | 64 |
| 192 | A young woman with cirrhosis: Autoimmune hepatitis vs. α 1-antitrypsin deficiency. Hepatology, 1994, 19, 1302-1306. | 7.3 | 4 |
| 193 | Acute Viral Hepatitis. , 0, , 2073-2111. | | 0 |